# Early Aggressive Strategy for Treatment of Lipid-Lowering in Acute Ischemic Stroke Delivered With Endovascular Therapy for Large Artery Occlusion

> **NCT07002476** · PHASE3 · RECRUITING · sponsor: **Shanghai East Hospital** · enrollment: 652 (estimated)

## Conditions studied

- Stroke

## Interventions

- **DRUG:** guideline-recommended SoC
- **DRUG:** Recaticimab (intensive)

## Key facts

- **NCT ID:** NCT07002476
- **Lead sponsor:** Shanghai East Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-19
- **Primary completion:** 2028-06-01
- **Final completion:** 2029-01-01
- **Target enrollment:** 652 (ESTIMATED)
- **Last updated:** 2026-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07002476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07002476, "Early Aggressive Strategy for Treatment of Lipid-Lowering in Acute Ischemic Stroke Delivered With Endovascular Therapy for Large Artery Occlusion". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07002476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*